This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
FAYAD, LUIS E
| Item Type | Name |
|
Academic Article
|
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
|
|
Academic Article
|
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
|
|
Academic Article
|
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
|
|
Academic Article
|
Bortezomib-resistant nuclear factor ?B expression in stem-like cells in mantle cell lymphoma.
|
|
Academic Article
|
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
|
|
Academic Article
|
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.
|
|
Academic Article
|
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
|
|
Academic Article
|
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
|
|
Academic Article
|
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma
|
|
Academic Article
|
Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.
|
|
Academic Article
|
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.
|
|
Academic Article
|
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
|
|
Concept
|
Bortezomib
|